Neuronal damage in general, and in SCI in particular, involves a long and complex cascade of secondary events following the injury itself. The complexity of the cascade can affect the efficiency of any treatments.
There is an unmet need and huge market potential for development of safe, efficient and convenient methods for treating SCI that provide recovery of motor function.
NurExone’s novel approach to SCI treatment is based on the perspective that intranasal exosome administration has broad potential and offers an alternative to other treatments that are under development to treat SCI.
Extensive research, conducted at Prof. Shulamit Levenberg’s lab at the Technion, Haifa in collaboration with Prof. Danny Offen from Tel Aviv University tested a novel proprietary treatment using intranasal administration of Exosomes derived from mesenchymal stem cells. Our exosomes were loaded with PTEN siRNA to target complete spinal cord lesion in rats. The research showed significant functional recovery.